Actis said it will hold a “significant stake” in the company, which manufactures cortico-steroid and steroid-hormone range of active pharmaceutical ingredients.
Partner and Head of South Asia at Actis JM Trivedi said, “Symbiotec is the leading Indian manufacturer of steroids-hormone APIs, a specialised pharmaceutical segment.
“With its USFDA approved facilities and high quality products with Asian cost manufacturing advantages, it is on track to become a leading global player. We look forward to working with Anil Satwani and his team to build on Symbiotec’s success to date.”
Last month it was reported that Actis planned to raise BRL385m ($163m) for its latest Brazil-focused energy fund.
Copyright © 2013 AltAssets